Aura Biosciences is leveraging a novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology.
Virus-Like Drug Conjugates (VDCs)
Our proprietary platform enables the targeting of a broad range of solid tumors using Virus-Like Particles, or VLPs, that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates, or VDCs.
Choroidal melanoma is a rare, vision- and life-threatening ocular cancer
There are no approved drug therapies for the first line treatment of choroidal melanoma and the current standard of care using radiotherapy leaves many patients with major vision loss, potential disfiguration, and a wide range of comorbidities. Despite the current treatments with radiotherapy, the long-term prognosis is poor with death occurring in more than 50% cases.
New options for early treatment intervention that preserve vision are urgently needed.